Key result
Sulfonylurea derivatives, particularly glibenclamide, are associated with a lower incidence of ventricular arrhythmias and no excess mortality in NIDDM patients with ischemic heart disease.
Why the study?
Are sulfonylurea derivatives safe to use in patients with NIDDM and ischemic heart disease?
Are sulfonylurea derivatives safe to use in patients with NIDDM and ischemic heart disease?
Despite experimental concerns about K.ATP channel blockade during ischemia, clinical evidence does not support withholding sulfonylureas from diabetic patients with ischemic heart disease.
No takes yet. Share an insight, caveat, or question.
May support sulfonylurea safety in NIDDM with ischemic heart disease; leaves open prospective randomized confirmation.
Carl E. Schotborgh (1997) conducted a review in Non-insulin-dependent diabetes mellitus (NIDDM) with ischemic heart disease. Sulfonylurea derivatives was evaluated. Sulfonylurea derivatives, particularly glibenclamide, are associated with a lower incidence of ventricular arrhythmias and no excess mortality in NIDDM patients with ischemic heart disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: